SAN JOSE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2025 and revised its 2025 revenue guidance. Third Quarter and Recent Highlights Net revenue of $29.4 million grew 3% from the prior year period, driven by an 8% increase in Tablo console revenue.Recurring revenue consisting of Tablo ...

Core Insights - Outset Medical, Inc. has announced new research findings from over 1 million Tablo hemodialysis treatments across approximately 750 facilities, highlighting the effectiveness of their technology in reducing the cost and complexity of dialysis [1][5] - The findings will be presented at the American Society of Nephrology's Kidney Week 2025, which is attended by over 12,000 professionals globally, emphasizing the significance of these results in the field of kidney care [2] Group 1: Research Findings - The studies indicate that insourcing dialysis services can elevate the standard of care in hospitals, providing both clinical benefits and significant cost savings [2] - Data from a large hospital in Florida showed a 94% reduction in serious cardiac or respiratory events and a sustained reduction in central-line bloodstream infections over five years [5] - A high nurse retention rate of over 95% and strong staff satisfaction were reported, alongside a strong return on investment within the first two years of operation [5] Group 2: Clinical Effectiveness - Data from 1 million Tablo treatments across more than 600 facilities supports the clinical effectiveness of insourced dialysis in achieving rigorous treatment goals [5] - Over 99% achievement of treatment goals was noted in 10,000 treatments prescribed for more than 23 hours, performed at approximately 150 hospitals, with minimal interruptions [5] Group 3: Technology Overview - The Tablo Hemodialysis System is designed to reduce the cost and complexity of dialysis, integrating water purification and on-demand dialysate production into a single system [6] - The system is FDA-cleared for use in both hospital and home settings, indicating its versatility and broad application [5][6] - Outset Medical aims to redefine kidney care through innovation and a commitment to improving patient and provider outcomes [6]

Core Insights - Outset Medical, Inc. will release its financial results for Q3 2025 on November 10, 2025, after market close [1] - A conference call will be held on the same day at 1:30 p.m. Pacific time to discuss the financial and operating results [2][3] Company Overview - Outset Medical is a medical technology company focused on transforming the dialysis experience with its innovative Tablo® Hemodialysis System, which is FDA-cleared for use in various healthcare settings [4] - The Tablo system integrates water purification and on-demand dialysate production, facilitating a seamless connection with Electronic Medical Record systems and a proprietary data analytics platform [4] - The company aims to empower healthcare providers to establish in-house dialysis programs, improving operational, clinical, and financial outcomes [4]

Core Insights - Outset Medical, Inc. reported a strong financial performance for Q2 2025, with revenue reaching $31.4 million, a 15% increase from $27.4 million in Q2 2024, driven by a 20% rise in product revenue [4][10] - The company is focused on transforming its commercial organization and has seen growing demand for its Tablo system, which offers clinical and operational benefits [3][10] - Operating expenses decreased by 29% year-over-year, reflecting the company's efforts to streamline operations and move towards profitability [6][10] Financial Performance - Total revenue for Q2 2025 was $31.4 million, up 15% from $27.4 million in Q2 2024, with product revenue at $23.1 million, a 20% increase from $19.2 million [4][10] - Gross profit increased by 21% to $11.9 million, with a gross margin of 37.8%, compared to 35.7% in the same quarter last year [5][10] - Net loss for the quarter was $18.5 million, significantly reduced from a net loss of $34.5 million in Q2 2024 [7][10] Operational Highlights - Recurring revenue from Tablo cartridges and services reached $22.5 million, an 11% increase compared to $20.2 million in the prior-year period [4][10] - The company signed a new enterprise agreement with a major national health system, expanding Tablo's access to over 100 facilities [10] - Tablo is now utilized in more than 900 acute and sub-acute sites across the U.S. [10] Future Guidance - Outset raised its 2025 revenue guidance to a range of $122 million to $126 million, up from the previous estimate of $115 million to $125 million [11] - The company anticipates a non-GAAP gross margin in the high-30% range for 2025 and expects to use less than $50 million in cash, compared to over $100 million in 2024 [11][10]

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [3] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [3] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [3] Product Features - The integration of water purification and on-demand dialysate production enables Tablo to function as a "dialysis clinic on wheels" [3] - Tablo features 2-way wireless data transmission and a proprietary data analytics platform, promoting a holistic approach to dialysis care [3] Upcoming Events - Management will present at the Goldman Sachs 46th Annual Healthcare Conference on June 11, 2025, at 11:20 a.m. Eastern time [1] - A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website [2]

Core Viewpoint - Outset Medical, Inc. has appointed Renee Gaeta as the new Chief Financial Officer, effective immediately, as the company aims to drive growth and achieve near-term profitability [1][2]. Company Overview - Outset Medical is a medical technology company focused on reducing the cost and complexity of dialysis through its innovative Tablo® Hemodialysis System, which is FDA cleared for use in various settings [4]. - The Tablo system integrates water purification and on-demand dialysate production, allowing for flexible dialysis delivery and operational simplification for providers [4]. Leadership Appointment - Renee Gaeta brings extensive financial and leadership experience from her previous roles as CFO at Shockwave Medical and Eko Health, among others [2][3]. - Gaeta's appointment is seen as a strategic move to support Outset's next phase of growth and profitability goals [2]. Financial Guidance - Outset has reiterated its financial guidance for 2025, projecting revenues between $115 million and $125 million, with a non-GAAP gross margin expected to be in the high-30% range [2].

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [4] - The company's flagship product, the Tablo® Hemodialysis System, is FDA cleared for use from hospital to home, representing a significant advancement in dialysis technology [4] - Tablo integrates water purification and on-demand dialysate production, allowing it to function as a mobile dialysis clinic with 2-way wireless data transmission and a proprietary data analytics platform [4] Leadership Changes - Kevin O'Boyle has been appointed to the Board of Directors and as chair of the Audit Committee, bringing over 20 years of healthcare leadership experience [2][3] - O'Boyle's previous roles include CFO of several publicly traded companies and board director of six public medical device companies, which will aid Outset in its growth [2] - Dale E. Jones has stepped down from the Board, with appreciation expressed for his contributions during a critical period for the company [3]

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [3] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [3] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [3] Technological Innovation - The integration of water purification and on-demand dialysate production enables Tablo to function as a "dialysis clinic on wheels" [3] - Tablo features 2-way wireless data transmission and a proprietary data analytics platform, promoting a holistic approach to dialysis care [3] Upcoming Events - Members of Outset's management will participate in the RBC Capital Markets Global Health Care conference on May 20, 2025, at 10:30 a.m. Eastern time [1] - A live and archived webcast of the session will be available on the "Investors" section of the Outset website [2]

Core Insights - Outset Medical, Inc. reported a 6% increase in revenue for Q1 2025, reaching $29.8 million compared to $28.2 million in Q1 2024, driven by strong performance in product and service revenues [4][9] - The company continues to demonstrate operational improvements, with a significant reduction in operating expenses by 39% year-over-year, contributing to a path toward profitability [6][11] - The installed base of the Tablo system is growing, with a notable increase in recurring revenue from consumables and services, which rose by 20% to $22.7 million [3][4][9] Financial Performance - Product revenue increased by 4% to $21.3 million, while service and other revenue grew by 9% to $8.5 million compared to the same period last year [4] - Gross profit for Q1 2025 was $11.1 million, a 35% increase from $8.2 million in Q1 2024, with gross margin improving to 37.2% from 29.2% [5][9] - The net loss narrowed to $25.8 million, or ($3.66) per share, compared to a net loss of $39.9 million, or ($11.77) per share in the prior year [8][9] Operational Highlights - The company shipped its 3 millionth Tablo treatment during the quarter, marking a significant milestone with 1 million treatments added over the past year [9] - Operating expenses were reduced to $27.5 million from $45.1 million in Q1 2024, with R&D expenses at $5.5 million, S&M expenses at $13.7 million, and G&A expenses at $8.3 million [6][8] - Non-GAAP operating expenses were reported at $24.6 million, reflecting ongoing efforts to streamline operations [7] Cash Position and Guidance - Total cash, including restricted cash and short-term investments, was $192 million as of March 31, 2025, following a financing round that provided approximately $210 million in cash [10][25] - The company reiterated its 2025 revenue guidance of $115 million to $125 million and expects to use less than $50 million in cash for the year, a significant reduction from $103 million used in 2024 [11]

Core Viewpoint - Outset Medical, Inc. has announced a one-for-fifteen reverse stock split, effective March 20, 2025, to reduce the number of outstanding shares and potentially enhance the stock's marketability [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on March 5, 2025, and will convert every 15 pre-split shares into one new share, reducing the total from approximately 265 million to about 17 million shares [2]. - The reverse stock split will not change stockholders' percentage ownership interests, except for fractional shares, which will be compensated with cash payments [3]. - The number of shares available under the Company's equity incentive plans and the exercise prices of outstanding options will be proportionately adjusted [4]. Group 2: Administrative Aspects - Equiniti Trust Company, LLC will act as the transfer agent for the reverse stock split, managing the issuance of post-split shares in a paperless format without requiring action from stockholders [5]. - Registered stockholders will automatically receive post-split shares, while those holding shares in "street name" will have their positions adjusted accordingly [5]. Group 3: Company Overview - Outset Medical is focused on pioneering technology to reduce the cost and complexity of dialysis, with its Tablo® Hemodialysis System representing a significant advancement in the field [7]. - The Tablo system allows for flexible dialysis delivery, integrating water purification and on-demand dialysate production, and is designed to enhance patient care and operational efficiency [7].